The prevalence of obesity in Asia is of epidemic proportions, with an estimated 1 billion overweight/obese individuals in the region. The majority of patients with type 2 diabetes mellitus (T2DM) are overweight/obese, which increases the risk of cardiorenal outcomes in these patients; hence, sustained reductions in body weight and visceral adiposity are important management goals. However, most of the glucose-lowering therapies such as insulin, sulfonylureas, glinides, and thiazolidinediones induce weight gain, which makes the management of overweight/obese T2DM patients challenging. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are the only oral glucose-lowering agents that have been shown to reduce body weight and visceral adiposity. In addition, SGLT-2 inhibitors therapy reduces ectopic fat deposition and improves adipose tissue function and weight-related quality of life. In this article, we aim to consolidate the existing literature on the effects of SGLT-2 inhibitors in Asian patients with T2DM and to produce clinical recommendations on their use in overweight or obese patients with T2DM. Recommendations from international and regional guidelines, as well as published data from clinical trials in Asian populations and cardiovascular outcomes trials are reviewed. Based on the available data, SGLT-2 inhibitors represent an evidence-based therapeutic option for the management of overweight/obese patients with T2DM.

Citations

Citations to this article as recorded by  

• The interaction between non-coding RNAs and SGLT2: A review
  Joanna Jarosz-Popek, Ceren Eyileten, Gloria M. Gager, Anna Nowak, Piotr Szwed, Zofia Wicik, Jeff Palatini, Dirk von Lewinski, Harald Sourij, Jolanta M. Siller-Matula, Marek Postula
  International Journal of Cardiology.2024; 398: 131419.     CrossRef
• A 52‐week efficacy and safety study of enavogliflozin versus dapagliflozin as an add‐on to metformin in patients with type 2 diabetes mellitus: ENHANCE‐M extension study
  Tae Seo Sohn, Kyung‐Ah Han, Yonghyun Kim, Byung‐Wan Lee, Suk Chon, In‐Kyung Jeong, Eun‐Gyoung Hong, Jang Won Son, JaeJin Na, Jae Min Cho, Seong In Cho, Wan Huh, Kun‐Ho Yoon
  Diabetes, Obesity and Metabolism.2024; 26(6): 2248.     CrossRef
• Comparison of the effects of empagliflozin and sitagliptin, as add-on to metformin, on serum levels of asprosin and metabolic parameters in patients with type 2 diabetes mellitus
  Seyed Saman Talebi, Shabnam Rezaie, Minoo Sadat Hajmiri, Maryam Zamanirafe, Akram Ranjbar, Heresh Moridi, Mahtabalsadat Mirjalili, Maryam Mehrpooya
  Naunyn-Schmiedeberg's Archives of Pharmacology.2024;[Epub]     CrossRef
• Long‐term efficacy and safety of enavogliflozin in Korean people with type 2 diabetes: A 52‐week extension of a Phase 3 randomized controlled trial
  Soo Heon Kwak, Kyung Ah Han, Eun Sook Kim, Sung Hee Choi, Jong Chul Won, Jae Myung Yu, Seungjoon Oh, Hye Jin Yoo, Chong Hwa Kim, Kyung‐Soo Kim, SungWan Chun, Yong Hyun Kim, Seung Ah Cho, Da Hye Kim, Kyong Soo Park
  Diabetes, Obesity and Metabolism.2024; 26(10): 4203.     CrossRef
• The effect of combining nutrient intake and physical activity levels on central obesity, sarcopenia, and sarcopenic obesity: a population-based cross-sectional study in South Korea
  Jong Eun Park, Seulgi Lee, Kirang Kim
  BMC Geriatrics.2023;[Epub]     CrossRef
• Increased risk of incident diabetes after therapy with immune checkpoint inhibitor compared with conventional chemotherapy: A longitudinal trajectory analysis using a tertiary care hospital database
  Minyoung Lee, Kyeongseob Jeong, Yu Rang Park, Yumie Rhee
  Metabolism.2023; 138: 155311.     CrossRef
• Efficacy and safety of janagliflozin as add‐on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double‐blind, placebo‐controlled, phase 3 trial
  Leili Gao, Zhifeng Cheng, Benli Su, Xiuhai Su, Weihong Song, Yushan Guo, Lin Liao, Xiaowen Chen, Jiarui Li, Xingrong Tan, Fangjiang Xu, Shuguang Pang, Kun Wang, Jun Ye, Yuan Wang, Lili Chen, Jingfang Sun, Linong Ji
  Diabetes, Obesity and Metabolism.2023; 25(3): 785.     CrossRef
• Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk
  Bains Jasleen, Gupta K Vishal, Malepati Sameera, Molla Fahad, O'Brien Brendan, Santander Deion, Sudhakar Pemminati
  Cureus.2023;[Epub]     CrossRef
• Safety and Effectiveness of Empagliflozin in Korean Patients with Type 2 Diabetes Mellitus: Results from a Nationwide Post-Marketing Surveillance
  Jun Sung Moon, Nam Hoon Kim, Jin Oh Na, Jae Hyoung Cho, In-Kyung Jeong, Soon Hee Lee, Ji-Oh Mok, Nan Hee Kim, Dong Jin Chung, Jinhong Cho, Dong Woo Lee, Sun Woo Lee, Kyu Chang Won
  Diabetes & Metabolism Journal.2023; 47(1): 82.     CrossRef
• Efficacy and Safety of Ertugliflozin Added to Metformin: A Pooled Population from Asia with Type 2 Diabetes and Overweight or Obesity
  Linong Ji, Jie Liu, Zhi Jin Xu, Zhiqi Wei, Ruya Zhang, Seema Malkani, Nilo B. Cater, Robert Frederich
  Diabetes Therapy.2023; 14(2): 319.     CrossRef
• Research Progress of Dapagliflozin in Treatment of Acute Myocardial Infarction Complicated with Type 2 Diabetes Mellitus
  鸿 王
  Advances in Clinical Medicine.2023; 13(02): 1667.     CrossRef
• Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis
  Hye Jin Chun, Eun Ran Kim, Minyoung Lee, Da Hyun Choi, Soo Hyun Kim, Eugene Shin, Jin-Hong Kim, Jin Won Cho, Dai Hoon Han, Bong-Soo Cha, Yong-ho Lee
  Metabolism.2023; 145: 155612.     CrossRef
• Efficacy and Safety of Enavogliflozin versus Dapagliflozin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus: A 24-Week, Double-Blind, Randomized Trial
  Kyung Ah Han, Yong Hyun Kim, Doo Man Kim, Byung Wan Lee, Suk Chon, Tae Seo Sohn, In Kyung Jeong, Eun-Gyoung Hong, Jang Won Son, Jae Jin Nah, Hwa Rang Song, Seong In Cho, Seung-Ah Cho, Kun Ho Yoon
  Diabetes & Metabolism Journal.2023; 47(6): 796.     CrossRef
• Renoprotection with sodium‐glucose cotransporter‐2 inhibitors in children: Knowns and unknowns
  Buchun Jiang, Zhiwen Cheng, Fei Liu, Qiuyu Li, Haidong Fu, Jianhua Mao
  Nephrology.2022; 27(2): 126.     CrossRef
• Mini Review: Effect of GLP-1 Receptor Agonists and SGLT-2 Inhibitors on the Growth Hormone/IGF Axis
  Angelo Cignarelli, Valentina Annamaria Genchi, Giulia Le Grazie, Irene Caruso, Nicola Marrano, Giuseppina Biondi, Rossella D’Oria, Gian Pio Sorice, Annalisa Natalicchio, Sebastio Perrini, Luigi Laviola, Francesco Giorgino
  Frontiers in Endocrinology.2022;[Epub]     CrossRef
• Sodium–glucose cotransporter 2 inhibitors do not increase the risk of fractures in real‐world clinical practice in Korea: A national observational cohort study
  Kyoung Hwa Ha, Dae Jung Kim, Yong Jun Choi
  Journal of Diabetes Investigation.2022; 13(6): 986.     CrossRef
• Liraglutide Alleviates Diabetic Atherosclerosis through Regulating Calcification of Vascular Smooth Muscle Cells
  Li-Li Shi, Ming Hao, Zhou-Yun Jin, Gui-Fang Peng, Ying-Ying Tang, Hong-Yu Kuang, Yaoyao Bian
  Disease Markers.2022; 2022: 1.     CrossRef
• Relationship Between Four Non-Insulin-Based Indexes of Insulin Resistance and Serum Uric Acid in Patients with Type 2 Diabetes: A Cross-Sectional Study
  Rongfeng Han, Yang Zhang, Xia Jiang
  Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2022; Volume 15: 1461.     CrossRef
• The dual role of empagliflozin: Cardio renal protection in T2DM patients
  Aimen Shafiq, Eman Mahboob, Muhammad Ammar Samad, Mohammad Hassam Ur Rehman, Zoaib Habib Tharwani
  Annals of Medicine & Surgery.2022;[Epub]     CrossRef
• Will GLP-1 Analogues and SGLT-2 Inhibitors Become New Game Changers for Diabetic Retinopathy?
  Katarzyna Wołos-Kłosowicz, Wojciech Matuszewski, Joanna Rutkowska, Katarzyna Krankowska, Elżbieta Bandurska-Stankiewicz
  Journal of Clinical Medicine.2022; 11(20): 6183.     CrossRef
• Tackling type 2 diabetes-associated cardiovascular and renal comorbidities: a key challenge for drug development
  Ernest A. Adeghate, Huba Kalász, Saeeda Al Jaberi, Jennifer Adeghate, Kornelia Tekes
  Expert Opinion on Investigational Drugs.2021; 30(2): 85.     CrossRef
• Henagliflozin as add‐on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double‐blind, placebo‐controlled, phase 3 trial
  Jianping Weng, Longyi Zeng, Yuwei Zhang, Shen Qu, Xueying Wang, Ping Li, Liujun Fu, Boqing Ma, Shandong Ye, Jiao Sun, Weiping Lu, Zhiwen Liu, Daoxiong Chen, Zhifeng Cheng, Haiyan Liu, Tao Zhang, Jianjun Zou
  Diabetes, Obesity and Metabolism.2021; 23(8): 1754.     CrossRef
• How do you treat obesity in the elderly pharmacologically?
  Claudio Daniel González, Guillermo Di Girolamo
  Expert Opinion on Pharmacotherapy.2021; 22(13): 1639.     CrossRef
• Case Report: Metreleptin and SGLT2 Inhibitor Combination Therapy Is Effective for Acquired Incomplete Lipodystrophy
  Ayako Nagayama, Kenji Ashida, Miki Watanabe, Kanoko Moritaka, Aya Sonezaki, Yoichiro Kitajima, Hirokazu Takahashi, Satoko Yoshinobu, Shimpei Iwata, Junichi Yasuda, Nao Hasuzawa, Shuichi Ozono, Seiichi Motomura, Masatoshi Nomura
  Frontiers in Endocrinology.2021;[Epub]     CrossRef
• New Pandemic: Obesity and Associated Nephropathy
  Isha Sharma, Yingjun Liao, Xiaoping Zheng, Yashpal S. Kanwar
  Frontiers in Medicine.2021;[Epub]     CrossRef
• Novel strategies for glycaemic control and preventing diabetic complications applying the clustering-based classification of adult-onset diabetes mellitus: A perspective
  Hayato Tanabe, Hiroaki Masuzaki, Michio Shimabukuro
  Diabetes Research and Clinical Practice.2021; 180: 109067.     CrossRef
• The SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients
  Mariana Tilinca, Robert Tiuca, Ioan Tilea, Andreea Varga
  Journal of Personalized Medicine.2021; 11(12): 1249.     CrossRef
• Lowering the risk of gout: Another benefits from the use of sodium–glucose cotransporter 2 inhibitors
  Wayne H‐H Sheu
  Journal of Diabetes Investigation.2020; 11(5): 1115.     CrossRef

• SGLT2 Inhibitors as Add-On Therapy to Metformin for People with Type 2 Diabetes: A Review of Placebo-Controlled Trials in Asian versus Non-Asian Patients

  
  André J Scheen
  Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2020; Volume 13: 2765.     CrossRef
• SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?
  Yoshifumi Saisho
  Diseases.2020; 8(2): 14.     CrossRef
• Roles of Epicardial Adipose Tissue in the Pathogenesis of Coronary Atherosclerosis　― An Update on Recent Findings ―
  Kimie Tanaka, Daiju Fukuda, Masataka Sata
  Circulation Journal.2020; 85(1): 2.     CrossRef

Citations

Citations to this article as recorded by  

• Associations between dietary patterns and renal impairment in individuals with diabetes: a cross‐sectional study
  Ziling Ding, Xingzhe Wu, Chao Liu, Ruixue Ying, Yi Zhang, Shiqi Zhang, Qiu Zhang, Honglin Hu, Fang Dai
  Journal of Human Nutrition and Dietetics.2024; 37(1): 193.     CrossRef
• A Randomised Controlled Study of Can Ling Bai Shu San Combined with Guizhi Fuling Pills and Dagliflozin in the Treatment of Proteinuria in Type 2 Diabetic Nephropathy Stage IV
  杰 张
  Advances in Clinical Medicine.2024; 14(01): 1829.     CrossRef
• Factors influencing optimal diabetes care and clinical outcomes in Thai patients with type 2 diabetes mellitus: a multilevel modelling analysis
  Apinya Surawit, Tanyaporn Pongkunakorn, Thamonwan Manosan, Pichanun Mongkolsucharitkul, Parinya Chamnan, Krishna Suvarnabhumi, Thanapat Puangpet, Sophida Suta, Sureeporn Pumeiam, Bonggochpass Pinsawas, Suphawan Ophakas, Sananon Pisitpornsuk, Chalita Utchi
  BMJ Open.2024; 14(5): e079415.     CrossRef
• Prevalence and characteristics of chronic kidney disease in people with type 2 diabetes mellitus in the Autonomous Community of Aragon
  María Antonia Sánchez-Calavera, Rafael Gómez Navarro, Elena Asso Otal, Isabel Blasco González, Daniel Escribano Pardo, Laia Homedes Celma, Michelot Lamarre, Pilar López Esteban, María Luisa Lozano del Hoyo, Liliana Mahulea, Inés Mera Gallego, Juan Carlos
  Primary Care Diabetes.2024; 18(5): 555.     CrossRef
• Cardiometabolic traits mediating the effect of education on the risk of DKD and CKD: a Mendelian randomization study
  Yukai Wang, Mengmeng Chen, Lin Wang, Yonggui Wu
  Frontiers in Nutrition.2024;[Epub]     CrossRef
• Evaluation of Renal Impairment in Patients with Diabetic Kidney Disease by Integrated Chinese and Western Medicine
  Yi-lun Qu, Zhe-yi Dong, Hai-mei Cheng, Qian Liu, Qian Wang, Hong-tao Yang, Yong-hui Mao, Ji-jun Li, Hong-fang Liu, Yan-qiu Geng, Wen Huang, Wen-hu Liu, Hui-di Xie, Fei Peng, Shuang Li, Shuang-shuang Jiang, Wei-zhen Li, Shu-wei Duan, Zhe Feng, Wei-guang Zh
  Chinese Journal of Integrative Medicine.2023; 29(4): 308.     CrossRef
• Extracellular status of thrombospondin-2 in type 2 diabetes mellitus and utility as a biomarker in the determination of early diabetic kidney disease
  Zhenzhen Lin, Didong Zhang, Xinxin Zhang, Wanxie Guo, Wenjun Wang, Yingchao Zhang, Zhen Liu, Yanxue Bi, Maolan Wu, Zhuofeng Lin, Xuemian Lu
  BMC Nephrology.2023;[Epub]     CrossRef
• Serum Lipocalin-2 Levels Are Increased and Independently Associated With Early-Stage Renal Damage and Carotid Atherosclerotic Plaque in Patients With T2DM
  Jing Gan, Yu Zheng, Qiongli Yu, Yingchao Zhang, Wei Xie, Yaru Shi, Ning Yu, Yu Yan, Zhuofeng Lin, Hong Yang
  Frontiers in Endocrinology.2022;[Epub]     CrossRef
• The Prevalence, Progress and Risk Factor Control of Chronic Kidney Disease in Chinese Adults With Type 2 Diabetes Mellitus in Primary Care
  Lingwang An, Qiuzhi Yu, Hong Tang, Xianglan Li, Dandan Wang, Qi Tang, Haiyang Xing, Yali He, Xiaona Zhao, Shuhui Zhao, Yaujiunn Lee, Juming Lu
  Frontiers in Endocrinology.2022;[Epub]     CrossRef
• Hydration status according to impedance vectors and its association with clinical and biochemical outcomes and mortality in patients with chronic kidney disease
  Paola Vanessa Miranda Alatriste, Eloísa Colin Ramírez, Ximena Atilano Carsi, Cristino Cruz-Rivera, Ángeles Espinosa-Cuevas
  Nutrición Hospitalaria.2022;[Epub]     CrossRef
• The Prevalence of Diabetic Microvascular Complications in China and the USA
  Yu Kuei Lin, Bixia Gao, Lili Liu, Lynn Ang, Kara Mizokami-Stout, Rodica Pop-Busui, Luxia Zhang
  Current Diabetes Reports.2021;[Epub]     CrossRef
• Reno-protective potential of sodium glucose cotransporter-2 (SGLT2) inhibitors: Summary evidence from clinical and real-world data
  Niti Mittal, Vikas Sehray, Rakesh Mittal, Surjit Singh
  European Journal of Pharmacology.2021; 907: 174320.     CrossRef
• Association between Renal Podocalyxin Expression and Renal Dysfunction in Patients with Diabetic Nephropathy: A Single-Center, Retrospective Case-Control Study
  Rongzhen Wang, Can Yao, Feng Liu
  BioMed Research International.2020; 2020: 1.     CrossRef
• Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk
  Francesco Giorgino, Jiten Vora, Peter Fenici, Anna Solini
  Cardiovascular Diabetology.2020;[Epub]     CrossRef
• Prevalence of diabetic nephropathy among Chinese patients with type 2 diabetes mellitus and different categories of their estimated glomerular filtration rate based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation in primary car
  Ka Yee Mok, Pang Fai Chan, Loretta K. P. Lai, Kai Lim Chow, David V. K. Chao
  Journal of Diabetes & Metabolic Disorders.2019; 18(2): 281.     CrossRef
• The association between serum uric acid to creatinine ratio and renal disease progression in type 2 diabetic patients in Chinese communities
  Yao Chunlei, Gu Liubao, Wang Tao, Xing Changying
  Journal of Diabetes and its Complications.2019; 33(7): 473.     CrossRef
• Risk factors of chronic kidney diseases in Chinese adults with type 2 diabetes
  Lin Yang, Tsun Kit Chu, Jinxiao Lian, Cheuk Wai Lo, Pak Ki Lau, Hairong Nan, Jun Liang
  Scientific Reports.2018;[Epub]     CrossRef
• Any grade of relative overhydration is associated with long-term mortality in patients with Stages 4 and 5 non-dialysis chronic kidney disease
  Almudena Vega, Soraya Abad, Nicolás Macías, Inés Aragoncillo, Ana García-Prieto, Tania Linares, Esther Torres, Andrés Hernández, José Luño
  Clinical Kidney Journal.2018; 11(3): 372.     CrossRef
• The impact of the quality of care and other factors on progression of chronic kidney disease in Thai patients with Type 2 Diabetes Mellitus: A nationwide cohort study
  Paithoon Sonthon, Supannee Promthet, Siribha Changsirikulchai, Ram Rangsin, Bandit Thinkhamrop, Suthee Rattanamongkolgul, Cameron P. Hurst, Cheng Hu
  PLOS ONE.2017; 12(7): e0180977.     CrossRef
• Association of Chronic Kidney Disease with Coronary Heart Disease and Stroke Risks in Patients with Type 2 Diabetes Mellitus
  Xue Sun, Jie He, Xiao-Li Ji, Yi-Ming Zhao, Han-Yu Lou, Xiao-Xiao Song, Li-Zhen Shan, Ying-Xiu Kang, Wen-Heng Zeng, Xiao-Hong Pang, Song-Zhao Zhang, Yue Ding, Yue-Zhong Ren, Peng-Fei Shan
  Chinese Medical Journal.2017; 130(1): 57.     CrossRef
• Prevalence of chronic kidney disease and associated factors in Chinese individuals with type 2 diabetes: Cross-sectional study
  Kaifeng Guo, Lei Zhang, Fangya Zhao, Junxi Lu, Pan Pan, Haoyong Yu, Yuqian Bao, Haibing Chen, Weiping Jia
  Journal of Diabetes and its Complications.2016; 30(5): 803.     CrossRef
• The association between abnormal heart rate variability and new onset of chronic kidney disease in patients with type 2 diabetes: A ten-year follow-up study
  Jae-Seung Yun, Yu-Bae Ahn, Ki-Ho Song, Ki-Dong Yoo, Hyung-Wook Kim, Yong-Moon Park, Seung-Hyun Ko
  Diabetes Research and Clinical Practice.2015; 108(1): 31.     CrossRef
• Association of elevated glycosylated hemoglobin A1c with hyperfiltration in a middle-aged and elderly Chinese population with prediabetes or newly diagnosed diabetes: a cross-sectional study
  Wen Hu, Hairong Hao, Weinan Yu, Xiaojuan Wu, Hongwen Zhou
  BMC Endocrine Disorders.2015;[Epub]     CrossRef
• Prevalence of Chronic Kidney Disease in Adults with Type 2 Diabetes Mellitus
  Serena KM Low, Chee Fang Sum, Lee Ying Yeoh, Subramaniam Tavintharan, Xiao Wei Ng, Simon BM Lee, Wern Ee Tang, Su Chi Lim
  Annals of the Academy of Medicine, Singapore.2015; 44(5): 164.     CrossRef
• Low Ankle-Brachial Index Is Associated with Early-Stage Chronic Kidney Disease in Type 2 Diabetic Patients Independent of Albuminuria
  Xuehong Dong, Dingting Wu, Chengfang Jia, Yu Ruan, Xiaocheng Feng, Guoxing Wang, Jun Liu, Yi Shen, Hong Li, Lianxi Li, Karin Jandeleit-Dahm
  PLoS ONE.2014; 9(10): e109641.     CrossRef
• Health Behaviors and Risk Factors Associated with Chronic Kidney Disease in Korean Patients with Diabetes: The Fourth Korean National Health and Nutritional Examination Survey
  Suk Jeong Lee, Chae Weon Chung
  Asian Nursing Research.2014; 8(1): 8.     CrossRef
• Urinary miR-29 Correlates with Albuminuria and Carotid Intima-Media Thickness in Type 2 Diabetes Patients
  Hui Peng, Meirong Zhong, Wenbo Zhao, Cheng Wang, Jun Zhang, Xun Liu, Yuanqing Li, Sujay Dutta Paudel, Qianqian Wang, Tanqi Lou, Emmanuel A. Burdmann
  PLoS ONE.2013; 8(12): e82607.     CrossRef
• Diabetes and its comorbidities—where East meets West
  Alice P. S. Kong, Gang Xu, Nicola Brown, Wing-Yee So, Ronald C. W. Ma, Juliana C. N. Chan
  Nature Reviews Endocrinology.2013; 9(9): 537.     CrossRef